Clinical trialsCompany release

Connect Biopharma reports Q3 loss, plans FDA Phase 3 talks for rademikibart

🇺🇸 Connect Biopharma Holdings Ltd (CNTB) · Mon 16 Nov 2026

The company says Phase 2 data for its IL-4Rα antibody in asthma and COPD exacerbations will underpin FDA meetings in December 2026 and the first quarter of 2027.

Connect Biopharma Holdings reported its third-quarter 2026 financial results on 16 November, posting a net loss of $16.2 million and cash of $19.5 million for the period.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Connect Biopharma Holdings Ltd ↗

Article written by VigiEye from the official source (Connect Biopharma Holdings Ltd). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →